Cocrystal Pharma Inc. (8CC)
XMUN 
Summary
8CC Chart
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Cocrystal Pharma, Inc. (COCP) could be a good stock pick from a technical perspective. COCP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Cocrystal Pharma Inc. (8CC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cocrystal Pharma Inc. ever had a stock split?
Cocrystal Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sam Lee CEO | XMUN Exchange | US19188J4094 ISIN |
| US Country | 11 Employees | - Last Dividend | 11 Oct 2022 Last Split | 19 May 2011 IPO Date |
Overview
Cocrystal Pharma, Inc. is a pioneering biotechnology firm focused on the discovery and development of novel antiviral treatments for serious and chronic viral diseases. Utilizing advanced structure-based technologies, the company crafts antiviral drugs aimed at combating hepatitis C virus (HCV), influenza, coronavirus, and norovirus infections. Based in Bothell, Washington, Cocrystal Pharma has forged key collaborations, including licensing and research agreements with Merck Sharp & Dohme Corp for influenza A/B antiviral agents, and a licensing agreement with Kansas State University Research Foundation for the development of treatments against norovirus and coronavirus infections.
Products and Services
-
CC-31244:
A non-nucleoside polymerase inhibitor specifically targeting HCV. This drug has successfully completed a Phase IIa clinical trial, demonstrating its potential as an effective treatment option for HCV infection.
-
CC-42344:
This PB2 inhibitor is designed to treat influenza infection and has completed a Phase I clinical trial. Its development is part of the company's broader strategy to address various strains of the influenza virus.
-
Non-nucleoside Polymerase Inhibitors for Norovirus:
Cocrystal Pharma is actively involved in the identification and development of novel non-nucleoside polymerase inhibitors aimed at treating norovirus infections, reflecting the company's commitment to tackling a broad range of viral diseases.
